Search results

Filter (5 in use)

Type

  • Filter by Guidance (1)

Status 1 selected

  • Filter by Published (63)
  • Filter by In development (18)
  • Filter by Proposed (9)
  • Remove filter for In consultation (1)

Last updated

  • Filter by Last 3 months
  • Filter by Last 6 months
  • Filter by Last year
  • Filter by Last 3 years

Guidance programme 4 selected

  • Filter by NICE guidelines (7)
  • Filter by Technology appraisal guidance (4)
  • Filter by Interventional procedures guidance (3)
  • Remove filter for Highly specialised technologies guidance (1)
  • Remove filter for Antimicrobial prescribing guidelines
  • Remove filter for Medicines practice guidelines
  • Remove filter for COVID-19 rapid guidelines

1 result

Sorted by Relevance . | Sort by Date

  • In consultation Remove In consultation filter
  • Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
  • Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
  • Medicines practice guidelines Remove Medicines practice guidelines filter
  • COVID-19 rapid guidelines Remove COVID-19 rapid guidelines filter
  1. Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]: evaluation consultation

    We are listening to your views on this highly specialised technology. Comments close 06 April 2021.

    Type
    Highly specialised technologies guidance
    Status
    In consultation